Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Enterprise Value (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Enterprise Value for 6 consecutive years, with -$84.0 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 32.4% to -$84.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$84.0 million through Dec 2025, up 32.4% year-over-year, with the annual reading at -$84.0 million for FY2025, 32.4% up from the prior year.
  • Enterprise Value for Q4 2025 was -$84.0 million at Relay Therapeutics, up from -$91.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$84.0 million in Q4 2025, with the low at -$354.6 million in Q3 2022.
  • Average Enterprise Value over 5 years is -$165.7 million, with a median of -$148.6 million recorded in 2023.
  • Peak annual rise in Enterprise Value hit 59.13% in 2021, while the deepest fall reached 273.49% in 2021.
  • Over 5 years, Enterprise Value stood at -$280.1 million in 2021, then soared by 45.81% to -$151.8 million in 2022, then grew by 5.31% to -$143.7 million in 2023, then rose by 13.53% to -$124.3 million in 2024, then skyrocketed by 32.4% to -$84.0 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$84.0 million, -$91.6 million, and -$113.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.